Arcturus Therapeutics (ARCT) Expected to Announce Quarterly Earnings on Monday

Key Points

• Arcturus Therapeutics (NASDAQ: ARCT) is set to announce its Q2 2025 earnings results on August 11th, with analysts predicting an earnings loss of ($1.11) per share and revenue of $17.64 million.
• In the previous quarter, the company reported an EPS of ($0.52) and revenue of $29.38 million, exceeding analysts' expectations.
• Institutional investors now own approximately 94.54% of Arcturus Therapeutics' stock, with several hedge funds making significant investments in the company recently.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) will likely be announcing its Q2 2025 earnings results after the market closes on Monday, August 11th. Analysts expect the company to announce earnings of ($1.11) per share and revenue of $17.64 million for the quarter.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($1.58) by $1.06. The business had revenue of $29.38 million during the quarter, compared to analyst estimates of $25.64 million. Arcturus Therapeutics had a negative net margin of 47.47% and a negative return on equity of 27.41%. On average, analysts expect Arcturus Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Arcturus Therapeutics Price Performance

Shares of ARCT traded down $0.10 during mid-day trading on Monday, reaching $12.20. The stock had a trading volume of 296,723 shares, compared to its average volume of 400,078. The firm has a market cap of $330.86 million, a price-to-earnings ratio of -4.82 and a beta of 2.26. Arcturus Therapeutics has a 12 month low of $8.04 and a 12 month high of $25.88. The business has a fifty day moving average of $13.17 and a 200 day moving average of $13.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.64 and a current ratio of 5.64.

Wall Street Analysts Forecast Growth

ARCT has been the subject of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Citigroup reiterated a "buy" rating on shares of Arcturus Therapeutics in a research report on Tuesday, May 13th. Scotiabank reiterated an "outperform" rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Canaccord Genuity Group dropped their target price on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Finally, Wells Fargo & Company dropped their target price on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Arcturus Therapeutics has an average rating of "Moderate Buy" and an average price target of $54.00.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of hedge funds have recently bought and sold shares of ARCT. Millennium Management LLC purchased a new stake in Arcturus Therapeutics during the first quarter valued at $4,892,000. Acadian Asset Management LLC purchased a new stake in Arcturus Therapeutics during the first quarter valued at $701,000. Goldman Sachs Group Inc. raised its stake in Arcturus Therapeutics by 9.1% during the first quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company's stock valued at $5,398,000 after purchasing an additional 42,636 shares in the last quarter. AQR Capital Management LLC purchased a new stake in Arcturus Therapeutics during the first quarter valued at $128,000. Finally, Strs Ohio purchased a new stake in Arcturus Therapeutics during the first quarter valued at $89,000. Hedge funds and other institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.